Business Context and Reporting Period
This Form 8-K filing by Galectin Therapeutics Inc. (GALT) reports events occurring on December 20, 2021, and December 21, 2021. The company, incorporated in Nevada and trading on the Nasdaq Capital Market, is an emerging growth company focused on therapeutic development.
Key Financial Metrics and Debt
The filing details a significant financing event rather than periodic financial performance metrics such as revenue or operating cash flow.
- New Debt: Execution of a second promissory note (December 2021 Note) for a principal amount of $10,000,000.
- Total Loan Agreement: This note is part of a broader $20,000,000 loan agreement with Richard E. Uihlein entered into in September 2021.
- Interest Rate: 2% per annum compounded annually, plus an additional 2.5% per quarter if the note is converted to equity.
- Maturity Date: December 20, 2025.
- Conversion Terms: Convertible into common stock at $5.43 per share (228% of the closing price on December 17, 2021).
- Line of Credit: A $10 million Line of Credit expiring December 31, 2021, was terminated upon closing this loan. There are currently no borrowings under this line.
Material Changes
The primary material change is the increase in debt obligations and potential equity dilution through the issuance of the $10 million convertible note. Additionally, the company terminated its existing Line of Credit facility, which had no outstanding borrowings at the time of termination.
Guidance, Outlook, and Risks
The filing does not provide specific revenue guidance, operational outlook, or management commentary beyond the terms of the financing. The primary risk disclosed relates to the potential dilution of existing shareholders if the noteholder elects to convert the debt into common stock at the specified conversion price. The sale of the note was exempt from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the total outstanding debt under the $20 million Loan Agreement with Richard E. Uihlein.
- Confirm the current share count to assess potential dilution if the $10 million note is converted at $5.43 per share.
- Review the full text of the Unsecured Convertible Promissory Note (Exhibit 10.1) for covenants or default provisions not summarized here.
- Check subsequent filings for any further draws on the loan agreement or changes to the conversion price.